Late Responses in Patients with Chronic Myeloid Leukemia Initially Refractory to Tyrosine Kinase Inhibitors

The introduction of tyrosine kinase inhibitor (TKI) therapy has dramatically improved outcomes for patients with chronic myeloid leukemia (CML); however, the prognosis for those who do not meet treatment milestones remains guarded. Here, we report our experience of patients with CML treated at a single center who did not achieve a complete cytogenetic response (CCyR) at 24 months.

Source: Clinical Lymphoma, Myeloma and Leukemia - July 18, 2021 Category: Hematology Authors: Justin Shaya, Kristen Pettit, Malathi Kandarpa, Dale Bixby, Jessica Mercer, Moshe Talpaz Source Type: research